A. Dinh-Xuan (Paris, France), P. Hassoun (Baltimore, United States of America)
Tyrosine kinase inhibition in pulmonary hypertension: the anti-proliferative approach R. T. Schermuly, E. Dony, H. A. Ghofrani, S. Pullamsetti, R. Savai, N. Weissmann, W. Seeger, F. Grimminger (Giessen, Germany)
| |
PDGF promotes pulmonary artery smooth muscle cell proliferation and migration in pulmonary arterial hypertension F. Perros, R. Souza, P. Doerfmuller, C. Tcherakian, G. Simonneau, M. Humbert (Clamart, France)
| |
Phosphodiesterase 1 upregulation in pulmonary arterial hypertension – target for anti-remodeling therapy R. T. Schermuly, X. Tian, R. Dumitrascu, S. Pullamsetti, G. Kwapiszewska, N. Weissmann, H. Ghofrani, T. Dunkern, H. Tenor, R. Voswinckel, W. Klepetko, R. Paddenberg, W. Kummer, W. Seeger, F. Grimminger (Giessen, Konstanz, Germany; Vienna, Austria)
| |
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil S. Schroll, D. Sebah, M. Arzt, R. Wensel, B. Stoelcker, M. Wagner, V. Popara, F. Blumberg, M. Pfeifer (Regensburg, Donaustauf, Germany)
| |
Pulmonary arterial hypertension (PAH) in mice lacking the vasoactive intestinal polypeptide (VIP) gene: morphometric evidence for vascular remodeling K. G. Dickman, S. A. Hamidi, A. M. Szema, S. I. Said (Stony Brook, Northport, United States Of America)
| |
PKC inhibits BKCa channel activity in pulmonary arterial smooth muscle cells through multiple signaling pathways S. Zhu, R. E. White, M. L. Meadows, S. A. Barman (Augusta, United States Of America)
| |
A central role for nuclear factor of activated T cells (NFAT) in human pulmonary arterial hypertension S. Bonnet, S. Archer, A. Haromy, E. Michelakis (Edmonton, Canada)
| |
Attenuated expression and activity of dimethylarginine dimethylaminohydrolase may play a key role in monocrotaline-induced pulmonary hypertension by accumulation of endogenous NOS inhibitors in rats A. Sasaki, S. Doi, H. Wakimoto, S. Mizutani, H. Azuma (Tokyo, Japan)
| |